US2015374730A1PendingUtilityA1

Cholestanol derivative for combined use

45
Assignee: UNIV GUNMA NAT UNIV CORPPriority: Mar 5, 2008Filed: Sep 3, 2015Published: Dec 31, 2015
Est. expiryMar 5, 2028(~1.6 yrs left)· nominal 20-yr term from priority
Inventors:Shin YazawaToyo NishimuraTakayuki Asao
A61P 35/00A61P 43/00A61K 45/06A61K 31/513A61K 31/664A61K 31/7072A61K 31/337A61K 31/724A61K 31/4745A61K 9/127A61K 31/704C07J 17/005A61K 31/282A61K 33/24A61K 33/243
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. The cancer chemotherapeutic agent of the invention includes a cholestanol derivative represented by formula (1): (wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal-, or GlcNAc-) or a cyclodextrin inclusion compound thereof, and an anti-cancer agent.

Claims

exact text as granted — not AI-modified
1 . A cancer chemotherapeutic agent comprising, in combination, a cholestanol derivative represented by formula (1): 
       
         
           
           
               
               
           
         
       
       (wherein G represents GlcNAc-Gal , or GlcNAc or a cyclodextrin inclusion compound thereof, and an anti-cancer agent selected from the group consisting of Paclitaxel, Docetaxcel, 5-fluorouracil, Cisplatin, Oxaliplatin, Pemetrexed, Cyclophosphamide, and Irinotecan. 
     
     
         2 - 10 . (canceled) 
     
     
         11 . The cancer chemotherapeutic agent of  claim 1 , which is a compounding agent. 
     
     
         12 . The cancer chemotherapeutic agent of  claim 11 , wherein the cholestanol derivative in the compounding agent is a liposomal formulation. 
     
     
         13 . The cancer chemotherapeutic agent of  claim 1 , which is in the form of a kit comprising a drug comprising a cholestanol derivative and a drug comprising an anti-cancer agent. 
     
     
         14 . The cancer chemotherapeutic agent of  claim 13 , wherein the drug comprising a cholestanol derivative is a liposomal formulation. 
     
     
         15 . A method of providing chemotherapy to a cancer patient in need thereof, the method comprising administering to the patient a cholestanol derivative represented by formula (1): 
       
         
           
           
               
               
           
         
       
       wherein G represents GlcNAc-Galor GlcNAc- or a cyclodextrin inclusion compound thereof, and an anti-cancer agent selected from the group consisting of Paclitaxel, Docetaxcel, 5-fluorouracil, Cisplatin, Oxaliplatin, Pemetrexed, Cyclophosphamide, and Irinotecan. 
     
     
         16 . The method of  claim 15 , wherein the cholestanol derivative and the anti-cancer agent are administered simultaneously. 
     
     
         17 . The method of  claim 15 , wherein the cholestanol derivative and the anti-cancer agent are administered separately. 
     
     
         18 . The method of  claim 15 , wherein the cholestanol derivative and the anti-cancer agent are administered intermittently.

Join the waitlist — get patent alerts

Track US2015374730A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.